Skip to main content

Day: September 6, 2024

Bedford Metals Provides Corporate Update on Uranium Exploration Progress

VANCOUVER, British Columbia, Sept. 06, 2024 (GLOBE NEWSWIRE) — Bedford Metals Corp. (TSX-V: BFM, FWB: O8D, ISIN: CA0762301012) (the “Company” or “Bedford”) wishes to provide a corporate update. Bedford continues to focus on advancing its uranium exploration projects in the Athabasca region of northern Saskatchewan, Canada and has made meaningful progress with its exploration initiatives. As reported in previous news releases, the Company has been actively advancing its exploration projects, particularly the Ubiquity Lake Uranium Project. Bedford is pleased with the initial results from its most recent exploration program, where the field team identified several promising targets. The Company is awaiting assay results from the samples collected during this program, which will provide further insight into the project’s potential. In...

Continue reading

TGS Awarded 2D Seismic Contract Offshore Sumatra, Indonesia

Perth, Australia (06 September 2024) – TGS, a leading global provider of energy data and intelligence, has commenced the acquisition of a 2D seismic survey in the Sumatra basin, Indonesia. The survey, conducted using COSL’s HYSY 718 vessel, is expected to comprise between 5,500- and 6,500-line kilometers, covering two regions. This initiative marks a continuation of TGS’s commitment to supporting exploration efforts in Indonesia. Earlier this year, TGS announced the completion of a multi-client 2D reprocessing project in the same basin which aims to integrate key discoveries with available open acreage, complementing TGS’s existing extensive 2D and 3D seismic datasets in the region. Kristian Johansen, CEO at TGS, stated, “North Sumatra has been the site of major discoveries in the past few years. With this being our sixth consecutive acquisition...

Continue reading

Construction contract in Estonia (office building in Tallinn)

On 5 September 2024, AS Merko Ehitus Eesti, part of AS Merko Ehitus group, and Estconde Invest OÜ entered into a design-and-build contract of an office building located at Tartu mnt 1, Tallinn. The contract includes construction of a 27-storey class A office building with two underground floors, necessary infrastructure and surrounding territory. The building will be completed according to the international BREEAM standard at the level Excellent. The contract value is approximately EUR 64.3 million, plus value added tax. The duration of the works is 40 months. AS Merko Ehitus Eesti (merko.ee) is a recognised Estonian construction company, which offers construction services in general construction, civil engineering and residential construction. Additional information: AS Merko Ehitus Eesti, Director of the General Construction Division,...

Continue reading

Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 25 million sales milestone payment to Basilea

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, September 6, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that sales of the antifungal Cresemba® (isavuconazole) by its license partner Pfizer in Europe exceeded the threshold that triggered a milestone payment of USD 25 million to Basilea. David Veitch, Chief Executive Officer of Basilea, said: “We are very pleased with the continued recognition of Cresemba in meeting the critical medical needs of patients with life-threatening invasive mold infections, and its strong sales performance in Europe, which has resulted in this milestone payment. We already announced several sales milestone payments from sales in Asia...

Continue reading

Bunker Hill Announces Election To Issue Shares in Satisfaction of Financing Cooperation Fee

VANCOUVER, British Columbia, Sept. 05, 2024 (GLOBE NEWSWIRE) — Bunker Hill Mining Corp. (“Bunker Hill” or the “Company”) (TSX-V: BNKR; OTCQB: BHLL) announces that it has elected to issue 506,775 shares of common stock (the “Shares”) at a deemed issue price of C$0.16 per Share to a certain creditor of the Company (the “Creditor”) in full satisfaction of the aggregate US$60,000 financing cooperation fee owing to the Creditor for the three (3) month period beginning on April 1, 2024 and ending on June 30, 2024 (the “Q2 Cooperation Fee”) pursuant to the terms of an agreement re financing cooperation dated September 27, 2022 (the “Cooperation Agreement”) entered into by and among the Company and the Creditor. The Cooperation Agreement provides for, among other things, the Creditor and its affiliates providing certain collateral security...

Continue reading

Varonis Systems, Inc. Announces Pricing of its Upsized $400 Million of Convertible Senior Notes

NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) — Varonis Systems, Inc. (Nasdaq: VRNS) (“Company” or “Varonis”), announced today that it priced a private offering of $400 million aggregate principal amount of 1.00% Convertible Senior Notes due 2029 (the “Notes”). The Notes will only be sold to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering size was increased from the previously announced offering size of $350 million aggregate principal amount of notes. The Company also granted to the initial purchasers of the Notes a 13-day option to purchase up to an additional $60 million aggregate principal amount of Notes. The sale is expected to close on September 10, 2024, subject to satisfaction of the conditions to closing. The...

Continue reading

Evergreen Corporation and Forekast Limited Announce Definitive Business Combination Agreement

Forekast connects today’s business needs to tomorrow’s technology. Forekast continues to innovate, offering flexible and scalable solutions tailored to meet the evolving needs of clients across multiple industries. NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) — Evergreen Corporation (NASDAQ: EVGR), a special purpose acquisition company (“EVGR”), today announced that they have entered into a definitive agreement and plan of merger (the “Business Combination Agreement”) under which EVGR will merge with Forekast Limited (“Forekast”). Following the closing, the combined company will operate as Forekast Group (“PubCo”). Forekast is a technology managed services provider specializing in augmented intelligence, integrating AI-driven insights to enhance business operations, customer experiences, and workforce capabilities. Forekast has a...

Continue reading

Alaska Energy Metals Closes $5 Million Special Warrant and Unit Offering; Nikolai Nickel Project Exploration Well Underway With More Than $8.68 Million Recently Raised

Highlights:An additional $5,000,000 has been raised in a second round of Special Warrant and Unit offerings, following on from first round offerings totaling $3,679,564 closed in July. More than $8.68 million has been raised between the two recent offerings. Alaska Energy Metals is now adequately funded for the drilling program planned and underway at the Nikolai nickel project in Alaska; drilling commenced in July and has been completed on the Canwell prospects. Drilling is underway to test for extensions of the Eureka nickel deposit. Metallurgical studies to determine metal recovery rates have been initiated.VANCOUVER, British Columbia, Sept. 05, 2024 (GLOBE NEWSWIRE) — Alaska Energy Metals Corporation (TSX-V: AEMC, OTCQB: AKEMF) (“AEMC” or the “Company”) is pleased to announce that it has closed its non-brokered offering...

Continue reading

UPDATE – Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia

Top-line data from VEGA-3 Phase 3 trial expected in first half of 2025 Top-line data from LYNX-2 Phase 3 trial in patients with decreased visual acuity under low light conditions following keratorefractive surgery expected in first quarter of 2025 FARMINGTON HILLS, Mich., Sept. 05, 2024 (GLOBE NEWSWIRE) — Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of patients with retinal and refractive eye disorders, today announced that the VEGA-3 Phase 3 clinical trial evaluating Phentolamine Ophthalmic Solution 0.75% for presbyopia has dosed its first participants. Presbyopia, the gradual loss of ability to focus on near objects, typically becomes noticeable in the early to mid-40s. This progressive and ubiquitous...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.